RxSight, Inc. (NASDAQ:RXST) CFO Sells $586,100.00 in Stock

RxSight, Inc. (NASDAQ:RXST) CFO Shelley B. Thunen sold 10,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $58.61, for a total transaction of $586,100.00. Following the transaction, the chief financial officer now owns 13,938 shares of the company’s stock, valued at approximately $816,906.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

RxSight Stock Down 0.1 %

RXST opened at $56.99 on Friday. RxSight, Inc. has a 12-month low of $20.66 and a 12-month high of $66.54. The business has a 50 day moving average of $58.74 and a 200-day moving average of $52.29.

RxSight (NASDAQ:RXST) last posted its quarterly earnings results on Monday, May 6th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.08). RxSight had a negative net margin of 44.01% and a negative return on equity of 27.68%. The business had revenue of $29.51 million during the quarter, compared to the consensus estimate of $27.56 million. During the same quarter last year, the company posted ($0.42) EPS. The firm’s revenue was up 68.7% on a year-over-year basis. Analysts forecast that RxSight, Inc. will post -0.77 EPS for the current year.

Institutional Trading of RxSight

A number of hedge funds have recently modified their holdings of the stock. RiverPark Advisors LLC raised its holdings in RxSight by 70.0% in the 4th quarter. RiverPark Advisors LLC now owns 668 shares of the company’s stock valued at $27,000 after acquiring an additional 275 shares during the period. Larson Financial Group LLC bought a new stake in RxSight in the 1st quarter valued at $51,000. Amalgamated Bank boosted its stake in RxSight by 7.7% in the 4th quarter. Amalgamated Bank now owns 4,148 shares of the company’s stock valued at $167,000 after purchasing an additional 298 shares during the period. Clear Rock Advisors LLC acquired a new position in RxSight in the 4th quarter valued at $172,000. Finally, Clarus Group Inc. bought a new position in RxSight during the 4th quarter worth $202,000. Institutional investors and hedge funds own 78.78% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on RXST shares. Needham & Company LLC boosted their price target on shares of RxSight from $64.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. BTIG Research upped their target price on RxSight from $61.00 to $72.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Stifel Nicolaus increased their price target on RxSight from $64.00 to $68.00 and gave the company a “buy” rating in a research report on Monday, May 6th. Oppenheimer upped their price objective on RxSight from $61.00 to $72.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 7th. Finally, Wells Fargo & Company increased their price objective on RxSight from $61.00 to $68.00 and gave the company an “overweight” rating in a report on Tuesday, May 7th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $60.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.